Nearly half of American doctors now have at least one patient who has told them they are using peptides. That is the headline number from a Sermo Barometer survey of 507 US-based clinicians fielded May 8-12, 2026 — 48% reported a patient disclosure of non-FDA-regulated peptide use in the prior twelve months, most often sourced through medspas, online research-use-only vendors, or compounding pharmacies.
The survey resurfaced on August 2, 2026, when Forbes used it to frame the widening gap between the FDA's own staff scientists and the agency's advisory committee, which voted in late July to recommend six of seven peptides for the 503A compounding list over staff objections. The physician data is the missing middle of that story: it describes what is actually happening in exam rooms while the regulatory question sits unresolved. For anyone already buying research peptides, it is also the clearest available picture of how that conversation tends to go.
Research-context information only. Compounds discussed below are research peptides and supplements; some are investigational drugs not approved by the FDA. Protocols, doses, and reactions reported come from published research and self-reported community sources. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
What the survey found
The Sermo Barometer sampled 507 US-based healthcare providers across cardiology, dermatology, endocrinology, internal medicine, neurology, and orthopedic surgery. The fieldwork window was May 8-12, 2026 — before the July PCAC vote, which means the numbers describe the pre-vote baseline rather than a reaction to it.
| Finding | Share of physicians |
|---|---|
| Had a patient disclose non-FDA-regulated peptide use in the past 12 months | 48% |
| Report patients citing social media, podcasts, influencers, or forums as a source | 84% |
| Say that happens "almost always" or "frequently" | 52% |
| Express concern about access outside clinical pathways | 66% |
| Say a clear FDA approval pathway is essential or very important | 81% |
| Cite unrealistic patient expectations as the biggest challenge | 33% |
| Report patient pressure to recommend non-FDA-approved treatments | 21% |
The stated reasons patients gave, per the same survey: weight loss (69%), anti-aging (57%), muscle gain (55%), and longevity (41%). That ordering tracks closely with what search and vendor demand already show — the metabolic category is the largest by a wide margin, with recovery and longevity compounds behind it.
One forward-looking data point stands out. Asked about triple-agonist agents — the class that includes retatrutide — 69% of relevant specialists said they expect strong patient interest once such a drug is approved, and 24% said patients are already asking about them today. Retatrutide's own Phase 3 program reported topline results across the TRIUMPH trials through mid-2026, with a regulatory filing signposted for 2027, so that anticipatory demand has a concrete timeline attached to it.
The information gap is the real finding
The 48% disclosure figure got the headline, but the 84% figure is the more consequential one. Across the surveyed population, the dominant information channel for patients using peptides was social media, podcasts, influencers, and forums — not clinicians, not package inserts, not primary literature. Just over half of respondents said that pattern showed up almost always or frequently.
That has a practical consequence that cuts in an unexpected direction. When physicians in the survey named their single biggest challenge with these conversations, the top answer was not an adverse event or a contamination scare. It was unrealistic expectations — 33%, well ahead of everything else. In other words, the friction doctors report is mostly an expectation-calibration problem created by the information source, not a clinical emergency created by the compound.
The second-order finding follows from it: 21% of respondents said they felt pressure from patients to recommend treatments that are not FDA-approved. That is a signal about how normalized the category has become. A therapy nobody is using does not generate that kind of pressure in an exam room.
None of this reads as a profession trying to shut the category down. 81% said a clear FDA approval pathway was essential or very important — a request for a defined route rather than a prohibition. That is the same thing the compounding-pharmacy industry has been asking for, from the opposite side of the table.
What it means if you already use peptides
The survey is descriptive, not regulatory. It does not change legal status, pricing, or availability for anything. What it does is give a reasonably accurate map of the room before the conversation starts.
Three things follow from the data:
Disclosure is now common enough to be unremarkable. At 48%, roughly one in two clinicians has already had this conversation with someone else. The scenario where a physician has never heard of BPC-157 or TB-500 is now the minority case, particularly in orthopedics, dermatology, and endocrinology.
Expectation framing is what physicians react to, not the compound. Since unrealistic expectations were the top-cited friction point at 33%, the material difference in these conversations tends to be whether the reported effect sizes are the ones the literature actually supports. Our per-peptide results-timeline articles and side-effect pages exist specifically to document what has been observed and over what horizon, with sourcing attached.
Baseline bloodwork is the part that carries over regardless of legal status. Independent of what the FDA does with the 503A list, the biomarkers relevant to a given compound — metabolic panel and A1c for the GLP-class agents, IGF-1 for growth-hormone secretagogues, CBC and inflammatory markers more broadly — do not change. Documented baselines are also what make an exam-room conversation concrete rather than anecdotal.
For what a given compound currently costs per milligram and which vendors publish third-party COAs, per-peptide pricing is tracked on the retatrutide, BPC-157, and TB-500 comparison pages. Active vendor codes are consolidated on the deals page.
